RGEN Stock Analysis: Repligen | NASDAQ

Bioprocessing Systems, Chromatography Resins, Filtration Devices, Process Analytics

Total Rating 48

Safety 91

Buy Signal 0.15

Medical Instruments & Supplies
Industry Rotation: +1.4

Market Cap: 11.7B
Avg Turnover: 229M

Risk 3d forecast

Volatility47.2%

VaR 5^th Pctl7.70%

VaR vs Median-1.00%

Reward TTM

Sharpe Ratio0.66

Rel. Str. IBD90.4

Rel. Str. Peer Group41.7 pctl

Character TTM

Beta0.898

Beta Downside0.424

Hurst Exponent0.455

Choppyness48.2%

Drawdowns 3y

Max DD50.64%

CAGR/Max DD0.23

CAGR/Mean DD0.42

EPS (Earnings per Share)

EPS CAGR: 19.26%
EPS Trend: 59.4%

Last SUE: 0.49
Qual. Beats: 0

Revenue

Rev. CAGR: 11.93%
Rev. Trend: 96.0%

Last SUE: 0.96
Qual. Beats: 2

Warnings

Interest Coverage Ratio Critical

Tailwinds

No distinct edge detected

Seasonality 11.7 years of data

Jan -3.8% 5

Feb -0.7% 17

Mar -4.2% 23

Apr +2.4% 5

May +1.9% 8

Jun +3.8% 18

Jul +5.1% 29

Aug +4.5% 37

Sep -5.0% 28

Oct -4.5% 44

Nov +8.3% 43

Dec -4.6% 39

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: RGEN Repligen

Repligen Corporation (NASDAQ: RGEN) is a life sciences company that develops and commercializes bioprocessing technologies and systems used in the manufacture of biological drugs. Headquartered in Waltham, Massachusetts and founded in 1981, the company sells its products globally across North America, Europe, and the Asia Pacific to biopharmaceutical and diagnostics companies, laboratory researchers, and contract manufacturing organizations (CMOs).

Its product portfolio spans consumables and instruments across several bioprocessing categories, including hollow fiber filtration consumables, the KRM chromatography system, Protein A affinity ligands and resins used in monoclonal antibody purification, ELISA test kits, OPUS pre-packed chromatography columns, and filtration systems such as the XCell ATF Cell Retention System, TangenX flat sheet cassettes, and KrosFlo tangential flow filtration systems. Repligen also offers a range of process analytics tools under the PATsmart family for real-time monitoring of critical bioprocess parameters, along with slope spectroscopy devices branded SoloVPE and FlowVPE.

The company markets its products under brands including OPUS, XCell, XCell ATF, KrosFlo, SIUS, ProConnex, Spectra/Por, NGL-Impact, SoloVPE, RPM, XO, Metenova MixOne, and AVIPure. Repligen maintains a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands, supporting its position in the affinity chromatography segment of the bioprocessing supply chain.

Headlines to Watch Out For

Bioprocessing revenue growth driven by gene therapy demand
Protein A resin margins face competition from Cytiva and Sartorius
Capital allocation shifts toward M&A and capacity expansion

Piotroski VR-10 (Strict) 3.0

Net Income: -11.8m TTM > 0 and > 6% of Revenue
FCF/TA: 0.04 > 0.02 and ΔFCF/TA -0.01 > 1.0
NWC/Revenue: 138.6% < 20% (prev 136.4%; Δ 2.20% < -1%)
CFO/TA 0.04 > 3% & CFO 129.9m > Net Income -11.8m
Net Debt (-30.8m) to EBITDA (125.9m): -0.25 < 3
Current Ratio: 9.88 > 1.5 & < 3
Outstanding Shares: last quarter (56.6m) vs 12m ago 0.07% < -2%
Gross Margin: 51.05% > 18% (prev 45.38%; Δ 5.67% > 0.5%)
Asset Turnover: 27.54% > 50% (prev 24.21%; Δ 3.33% > 0%)
Interest Coverage Ratio: 0.97 > 6 (EBIT TTM 33.8m / Interest Expense TTM 34.9m)

Altman Z'' 5.69

A: 0.38 (Total Current Assets 1.24b - Total Current Liabilities 125.7m) / Total Assets 2.93b
B: 0.15 (Retained Earnings 431.2m / Total Assets 2.93b)
C: 0.01 (EBIT TTM 33.8m / Avg Total Assets 2.93b)
D: 2.51 (Book Value of Equity 2.09b / Total Liabilities 834.7m)
Altman-Z'' = 5.69 = AAA

Beneish M -3.16

DSRI: 0.89 (Receivables 151.2m/149.0m, Revenue 805.6m/707.9m)
GMI: 0.89 (GM 45.38% / 51.05%)
AQI: 0.93 (AQ_t 0.48 / AQ_t-1 0.52)
SGI: 1.14 (Revenue 805.6m / 707.9m)
TATA: -0.05 (NI -11.8m - CFO 129.9m) / TA 2.93b)
Beneish M = -3.16 (Cap -4..+1) = AA

What is the price of RGEN shares?

As of October 30, 2026, the stock is trading at USD 188.64 with a total of 886,116 shares traded. Over the past week, the price has changed by +5.56%, over one month by -3.05%, over three months by +33.57% and over the past year by +27.05%.

Current recommended Stop Loss: 177.60 (which is 5.9% or 1.2 ATR below the current price).

Is RGEN a buy, sell or hold?

Repligen has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy RGEN.

StrongBuy: 15
Buy: 3
Hold: 4
Sell: 0
StrongSell: 0

What are the forecasts/targets for the RGEN price?

Analysts Target Price	202.2	7.2%

Repligen (RGEN) - Fundamental Data Overview as of 30 October 2026

Market Cap USD = 11.7b (11.7b USD * 1.0 USD.USD)
P/E Forward = 64.1026
P/S = 14.5555
P/B = 5.3421
P/EG = 1.755
Revenue TTM = 805.6m USD
EBIT TTM = 33.8m USD
EBITDA TTM = 125.9m USD
Long Term Debt = 542.2m USD (from longTermDebt, last fiscal year)
Short Term Debt = 20.4m USD (from shortTermDebt, last quarter)
Debt = 832.1m USD (from shortLongTermDebtTotal, last quarter) + Leases 139.9m
Net Debt = -30.8m USD (calculated: Debt 832.1m - CCE 863.0m)
Enterprise Value = 11.7b USD (11.7b + Debt 832.1m - CCE 863.0m)
Interest Coverage Ratio = 0.97 (Ebit TTM 33.8m / Interest Expense TTM 34.9m)
EV/FCF = 110.1x (Enterprise Value 11.7b / FCF TTM 106.2m)
FCF Yield = 0.91% (FCF TTM 106.2m / Enterprise Value 11.7b)
FCF Margin = 13.18% (FCF TTM 106.2m / Revenue TTM 805.6m)
Net Margin = -1.47% (Net Income TTM -11.8m / Revenue TTM 805.6m)
Gross Margin = 51.05% ((Revenue TTM 805.6m - Cost of Revenue TTM 394.3m) / Revenue TTM)
Gross Margin QoQ = 53.02% (prev 53.08%)
Tobins Q-Ratio = 4.00 (Enterprise Value 11.7b / Total Assets 2.93b)
Interest Expense / Debt = 4.19% (Interest Expense 34.9m / Debt 832.1m)
Taxrate = 21.62% (13.5m / 62.4m)
NOPAT = 26.5m (EBIT 33.8m * (1 - 21.62%))
Current Ratio = 9.88 (Total Current Assets 1.24b / Total Current Liabilities 125.7m)
Debt / Equity = 0.40 (Debt 832.1m / totalStockholderEquity, last quarter 2.09b)
Debt / EBITDA = -0.25 (Net Debt -30.8m / EBITDA 125.9m)
Debt / FCF = -0.29 (Net Debt -30.8m / FCF TTM 106.2m)
Total Stockholder Equity = 2.10b (last 4 quarters mean from totalStockholderEquity)
RoA = -0.40% (Net Income -11.8m / Total Assets 2.93b)
RoE = -0.56% (Net Income TTM -11.8m / Total Stockholder Equity 2.10b)
RoCE = 1.28% (EBIT 33.8m / Capital Employed (Equity 2.10b + L.T.Debt 542.2m))
RoIC = 0.95% (NOPAT 26.5m / Invested Capital 2.78b)
WACC = 8.30% (E(11.7b)/V(12.6b) * Re(8.66%) + D(832.1m)/V(12.6b) * Rd(4.19%) * (1-Tc(0.22)))
Discount Rate = 8.66% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 17.56 | Cagr: 0.10%
[DCF] Terminal Value 75.41% ; FCFF base≈106.3m ; Y1≈106.5m ; Y5≈112.4m
[DCF] Fair Price = 28.03 (EV 1.75b - Net Debt -30.8m = Equity 1.78b / Shares 63.5m; r=8.35% [WACC [floored]]; 5y FCF grow -0.25% → 2.50% )
EPS Correlation: 59.40 | EPS CAGR: 19.26% | SUE: 0.49 | # QB: 0
Revenue Correlation: 96.01 | Revenue CAGR: 11.93% | SUE: 0.96 | # QB: 2
EPS current Quarter (2027-03-31): EPS=0.59 | Chg30d=+0.46% | Revisions=+10% | Analysts=9
EPS current Year (2026-12-31): EPS=2.07 | Chg30d=+0.43% | Revisions=-29% | GrowthEPS=+21.3% | GrowthRev=+15.0%
EPS next Year (2027-12-31): EPS=2.65 | Chg30d=+0.47% | Revisions=-29% | GrowthEPS=+27.6% | GrowthRev=+26.0%
[Analyst] Revisions Ratio: -17% (up=6, down=9)